Abstract: The disclosure concerns antibodies that bind and antagonize CD40. These antibodies are particularly useful to inhibit immune responses and treat auto-immune diseases.

Abstract: The disclosure concerns antibodies that bind and antagonize CD40. These antibodies are particularly useful to inhibit immune responses and treat auto-immune diseases.

Abstract: The disclosure concerns antibodies that bind and antagonize CD40. These antibodies are particularly useful to inhibit immune responses and treat auto-immune diseases.

Abstract: The disclosure concerns antibodies that bind fibronectin-EDA. These antibodies are particularly useful for use in treatment, prevention, or prevention of progression of fibrosis, adverse cardiac remodeling and conditions resulting from or relating to myocardial infarction and pressure-overload, such as heart failure, aneurysm formation and remote myocardial fibrosis and for use in improving angiogenesis, preferably after ischemic injury.

Abstract: The invention provides a CD40 signalling inhibitor and a further compound for use in the treatment of chronic inflammatory disease in an individual in need thereof, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR-receptor agonist or a combination thereof. Also provided is a CD40 signalling inhibitor and a further compound for use in the prevention of cancer and/or fibrosis, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR-receptor agonist or a combination thereof.

Abstract: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.

Abstract: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.

Abstract: The invention provides a method of treatment of hot flush with S-mirtazapine and the use of S-mirtazapine for the manufacture of a medicament for the treatment of hot flush.

Abstract: The invention relates to bisaryl derivatives of the formula I, wherein (R,R) is selected from (H,H), O, (H,CH3), (H,OH) and (H,CN); Ar is substituted phenyl and A is a group of formula II, III, IV or V: An example is (3S,6S)-1-N-(7-phenylheptyl)-3-(4-(3,4,5-trimethoxyphenyl)benzyl)-4-N-methyl-6-methyl-2,5-dioxo-1,4-piperazine: The compounds of the invention have FSH receptor modulatory activity and can be used for the control of fertility, for contraception or for treatment of hormone-dependent disorders.

Abstract: The invention relates to a bicyclic heteroaromatic derivative compound according to general formula (II), or a pharmaceutically acceptable salt thereof. The compounds of the invention have LH receptor activating activity and can be used in fertility regulating therapies.

Abstract: The invention relates to bisaryl derivatives of the formula I, 1

Abstract: The invention relates to a compound having the formula (I): R1SO2—B—X—Z—C(O)—Y, B is a bond, an amino acid of the formula —NR—CH[(CH2)pC(O)OH]—C(O)— or an ester derivative thereof wherein p is 1, 2, or 3, Gly, D-1-Piq, D-3-Piq, D-1-Tiq, D-3-Tiq, D-Atc, Aic, or a L- or D-amino acid having a hydrophobic, basic or neutral side chain; X is an amino acid with a hydrophobic side chain, glutamine, serine, theronine, a cyclic amino acid optionally containing an additional heteroatom selected from N, O or S, and optionally substituted with (1-6C)alkyl, (1-6C)alkoxy, benzyloxy or oxo, or X is 2-amino-isobutyric acid, —NR2—CH2—C(O)— or the fragment (I) or (II), wherein n is 2, 3, or 4, W is CH or N and R3 is H, (1-6C)alkyl or phenyl which groups may optionally be substituted with hydroxy, (1-6C)alkoxy, COOH, COO(1-6C)alkyl, CONH2, or halogen; Z is lysine or 4-aminocyclohexylglycine.

Abstract: Serine protease inhibitors, prodrugs thereof and pharmaceutically acceptable salts thereof are disclosed. The serine protease inhibitors exhibit anticoagulant activity and are useful for treating or preventing thrombin related diseases.

Abstract: The invention relates to a cornound having formula (I), wherein A, B, X, Y and r are as defined in the description, or a prodrug thereof or a pharnnaceutically acceptable salt thereof. The compounds of the invention have anticoagulant activity and can be used in treating or preventing thrombin-related diseases.

Abstract: The invention relates to a compound having formula (I), wherein A, B, X, N, Z and Q are defined as described in the description. The compounds of the invention have anticoagulant activity and can be used in treating or preventing thrombin-related diseases.

Abstract: The invention relates to an imidazole?1,5a!pyridine derived serine protease inhibitor comprising a unit having general formula (I) ##STR1## wherein R.sub.1 is hydrogen, lower alkyl or an acyl group; R.sub.2 is hydrogen or lower alkyl; R.sub.3 and R.sub.4 are independently hydrogen, lower alkyl or together form .dbd.CH--NR.sub.5 NR.sub.6, R.sub.5 and R.sub.6 being lower alkyl. The compounds are serine protease inhibitors and can be used for the treatment and prophylaxis of thrombosis and thrombin-associated diseases.

Abstract: The invention relates to a thrombin inhibitor of the formula:R.sup.1 NH--CHR.sup.2 --C(O)--A--B--X (I)wherein R.sup.1 is -(1-6C)alkylene-COOH or -(1-6C)alkylene-CONH.sub.2 ;R.sup.2 is a side chain of a hydrophobic D-amino acid;A is an amino acid selected from proline, optionally containing a second heteroatom selected from N, O, or S, and optionally substituted with (1-6C)alkyl, (1-6C)alkoxy or halogen, 2-azetidine carboxylic acid, pipecolinic acid, octahydroindole-2-carboxylic acid or valine;B is lysine, 3- or 4-aminocyclohexylglycine or .omega.-(1-6C)alkyl-lysine; andX is a heterocycle selected from 2-thiazole, 2-thiazoline, 2-benzothiazole, 2-oxazole, 2-oxazoline, 2-benzoxazole, 2-imidazole and 2-benzimidazole, which heterocycles are optionally substituted with one or more substituents selected from (1-6C)alkyl, (1-6C)alkoxy, oxo, hydroxy, halogen, phenyl, --C(O)O--(1-6C)alkyl and amido; or a pharmaceutically acceptable salt thereof.